Janus kinase 2

PDB rendering based on 2b7a.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols JAK2; JTK10; THCYT3
External IDs OMIM: 147796 MGI: 96629 HomoloGene: 21033 ChEMBL: 2971 GeneCards: JAK2 Gene
EC number 2.7.10.2
Orthologs
Species Human Mouse
Entrez 3717 16452
Ensembl ENSG00000096968 ENSMUSG00000024789
UniProt O60674 Q62120
RefSeq (mRNA) NM_004972.3 NM_001048177.1
RefSeq (protein) NP_004963.1 NP_001041642.1
Location (UCSC) Chr 9:
4.99 – 5.13 Mb		 Chr 19:
29.33 – 29.39 Mb
PubMed search [1] [2]
This box:

Janus kinase 2 (commonly called JAK2) is a human protein that has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g. IL-6R), and the single chain receptors (e.g. Epo-R, Tpo-R, GH-R, PRL-R). JAK2 signaling is activated downstream from the prolactin receptor.[1]

Loss of Jak2 is lethal by embryonic day 12 in mice.[2]

JAK2 orthologs [3] have been identified in all mammals for which complete genome data are available.

Contents

Clinical significance [link]

JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in leukemia patients.[4][5] Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, myelofibrosis as well as other myeloproliferative disorders.[6] This mutation, (V617F) a change of valine to phenylalanine at the 617 position, appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin.

Interactions [link]

Janus kinase 2 has been shown to interact with Growth hormone receptor,[7][8][9] Protein arginine methyltransferase 5,[10] STAT5A,[11][12] STAT5B,[11][12] Interleukin 12 receptor, beta 2 subunit,[13] PIK3R1,[14] SH2B1,[15][16] SHC1,[17][18] TEC,[19][20] SOCS3,[21][22][23] PTPN11,[24][25][26] PTPN6,[27][28] Interleukin 5 receptor alpha subunit,[29] Grb2,[30][31] Suppressor of cytokine signaling 1,[23][32][33][34][35][36] VAV1,[37][38] FYN,[39] Epidermal growth factor receptor,[40] PTK2,[41][42] TNFRSF1A,[43] Erythropoietin receptor,[44][45] YES1,[14] IRS1,[46][47] DNAJA3,[48] Signal transducing adaptor molecule[49] and PPP2R4.[14] Prolactin signals through JAK2 are dependent on STAT5, and on the RUSH transcription factors [50]

See also [link]

References [link]

  1. ^ Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998). "Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice". Endocr. Rev. 19 (3): 225–68. DOI:10.1210/er.19.3.225. PMID 9626554. 
  2. ^ Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K (1998). "Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis". Cell 93 (3): 397–409. DOI:10.1016/S0092-8674(00)81168-X. PMID 9590174. 
  3. ^ "OrthoMaM phylogenetic marker: JAK2 coding sequence". https://www.orthomam.univ-montp2.fr/orthomam/data/cds/detailMarkers/ENSG00000096968_JAK2.xml. 
  4. ^ Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffé M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA (1997). "A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia". Science 278 (5341): 1309–12. DOI:10.1126/science.278.5341.1309. PMID 9360930. 
  5. ^ Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005). "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2". Cancer Res. 65 (7): 2662–7. DOI:10.1158/0008-5472.CAN-04-4263. PMID 15805263. 
  6. ^ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. DOI:10.1056/NEJMoa051113. PMID 15858187. 
  7. ^ Frank, S J; Yi W, Zhao Y, Goldsmith J F, Gilliland G, Jiang J, Sakai I, Kraft A S (June 1995). "Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor". J. Biol. Chem. (UNITED STATES) 270 (24): 14776–85. DOI:10.1074/jbc.270.24.14776. ISSN 0021-9258. PMID 7540178. 
  8. ^ VanderKuur, J A; Wang X, Zhang L, Campbell G S, Allevato G, Billestrup N, Norstedt G, Carter-Su C (August 1994). "Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase". J. Biol. Chem. (UNITED STATES) 269 (34): 21709–17. ISSN 0021-9258. PMID 8063815. 
  9. ^ Hellgren, G; Jansson J O, Carlsson L M, Carlsson B (June 1999). "The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver". Growth Horm. IGF Res. (SCOTLAND) 9 (3): 212–8. DOI:10.1054/ghir.1999.0111. ISSN 1096-6374. PMID 10502458. 
  10. ^ Pollack, B P; Kotenko S V, He W, Izotova L S, Barnoski B L, Pestka S (October 1999). "The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity". J. Biol. Chem. (UNITED STATES) 274 (44): 31531–42. DOI:10.1074/jbc.274.44.31531. ISSN 0021-9258. PMID 10531356. 
  11. ^ a b Barahmand-Pour, F; Meinke A, Groner B, Decker T (May. 1998). "Jak2-Stat5 interactions analyzed in yeast". J. Biol. Chem. (UNITED STATES) 273 (20): 12567–75. DOI:10.1074/jbc.273.20.12567. ISSN 0021-9258. PMID 9575217. 
  12. ^ a b Fujitani, Y; Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T (February 1997). "An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT". Oncogene (ENGLAND) 14 (7): 751–61. DOI:10.1038/sj.onc.1200907. ISSN 0950-9232. PMID 9047382. 
  13. ^ Yamamoto, K; Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N (April 1999). "Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus". Biochem. Biophys. Res. Commun. (UNITED STATES) 257 (2): 400–4. DOI:10.1006/bbrc.1999.0479. ISSN 0006-291X. PMID 10198225. 
  14. ^ a b c Fuhrer, D K; Yang Y C (July 1996). "Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11". Biochem. Biophys. Res. Commun. (UNITED STATES) 224 (2): 289–96. DOI:10.1006/bbrc.1996.1023. ISSN 0006-291X. PMID 8702385. 
  15. ^ Rui, L; Mathews L S, Hotta K, Gustafson T A, Carter-Su C (November 1997). "Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling". Mol. Cell. Biol. (UNITED STATES) 17 (11): 6633–44. ISSN 0270-7306. PMC 232517. PMID 9343427. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=232517. 
  16. ^ Xie, Shanhai; Lin Hui, Sun Tong, Arlinghaus Ralph B (October 2002). "Jak2 is involved in c-Myc induction by Bcr-Abl". Oncogene (England) 21 (47): 7137–46. DOI:10.1038/sj.onc.1205942. ISSN 0950-9232. PMID 12370803. 
  17. ^ VanderKuur, J; Allevato G, Billestrup N, Norstedt G, Carter-Su C (March 1995). "Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2". J. Biol. Chem. (UNITED STATES) 270 (13): 7587–93. DOI:10.1074/jbc.270.13.7587. ISSN 0021-9258. PMID 7535773. 
  18. ^ Giordano, V; De Falco G, Chiari R, Quinto I, Pelicci P G, Bartholomew L, Delmastro P, Gadina M, Scala G (May. 1997). "Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase". J. Immunol. (UNITED STATES) 158 (9): 4097–103. ISSN 0022-1767. PMID 9126968. 
  19. ^ Takahashi-Tezuka, M; Hibi M, Fujitani Y, Fukada T, Yamaguchi T, Hirano T (May. 1997). "Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK". Oncogene (ENGLAND) 14 (19): 2273–82. DOI:10.1038/sj.onc.1201071. ISSN 0950-9232. PMID 9178903. 
  20. ^ Yamashita, Y; Watanabe S, Miyazato A, Ohya K i, Ikeda U, Shimada K, Komatsu N, Hatake K, Miura Y, Ozawa K, Mano H (March 1998). "Tec and Jak2 kinases cooperate to mediate cytokine-driven activation of c-fos transcription". Blood (UNITED STATES) 91 (5): 1496–507. ISSN 0006-4971. PMID 9473212. 
  21. ^ Sasaki, A; Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A (September 2000). "CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2". J. Biol. Chem. (UNITED STATES) 275 (38): 29338–47. DOI:10.1074/jbc.M003456200. ISSN 0021-9258. PMID 10882725. 
  22. ^ Sasaki, A; Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston J A, Yoshimura A (June 1999). "Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain". Genes Cells (ENGLAND) 4 (6): 339–51. DOI:10.1046/j.1365-2443.1999.00263.x. ISSN 1356-9597. PMID 10421843. 
  23. ^ a b Masuhara, M; Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A (October 1997). "Cloning and characterization of novel CIS family genes". Biochem. Biophys. Res. Commun. (UNITED STATES) 239 (2): 439–46. DOI:10.1006/bbrc.1997.7484. ISSN 0006-291X. PMID 9344848. 
  24. ^ Yin, T; Shen R, Feng G S, Yang Y C (January 1997). "Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases". J. Biol. Chem. (UNITED STATES) 272 (2): 1032–7. DOI:10.1074/jbc.272.2.1032. ISSN 0021-9258. PMID 8995399. 
  25. ^ Tauchi, T; Damen J E, Toyama K, Feng G S, Broxmeyer H E, Krystal G (June 1996). "Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis". Blood (UNITED STATES) 87 (11): 4495–501. ISSN 0006-4971. PMID 8639815. 
  26. ^ Maegawa, H; Kashiwagi A, Fujita T, Ugi S, Hasegawa M, Obata T, Nishio Y, Kojima H, Hidaka H, Kikkawa R (November 1996). "SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates". Biochem. Biophys. Res. Commun. (UNITED STATES) 228 (1): 122–7. DOI:10.1006/bbrc.1996.1626. ISSN 0006-291X. PMID 8912646. 
  27. ^ Jiao, H; Berrada K, Yang W, Tabrizi M, Platanias L C, Yi T (December 1996). "Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1". Mol. Cell. Biol. (UNITED STATES) 16 (12): 6985–92. ISSN 0270-7306. PMC 231702. PMID 8943354. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=231702. 
  28. ^ Wu, D W; Stark K C, Dunnington D, Dillon S B, Yi T, Jones C, Pelus L M (February 2000). "SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells". Blood Cells Mol. Dis. (UNITED STATES) 26 (1): 15–24. DOI:10.1006/bcmd.2000.0273. ISSN 1079-9796. PMID 10772872. 
  29. ^ Ogata, N; Kouro T, Yamada A, Koike M, Hanai N, Ishikawa T, Takatsu K (April 1998). "JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation". Blood (UNITED STATES) 91 (7): 2264–71. ISSN 0006-4971. PMID 9516124. 
  30. ^ Chauhan, D; Kharbanda S M, Ogata A, Urashima M, Frank D, Malik N, Kufe D W, Anderson K C (December 1995). "Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells". J. Exp. Med. (UNITED STATES) 182 (6): 1801–6. DOI:10.1084/jem.182.6.1801. ISSN 0022-1007. PMC 2192257. PMID 7500025. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2192257. 
  31. ^ Giorgetti-Peraldi, S; Peyrade F, Baron V, Van Obberghen E (December 1995). "Involvement of Janus kinases in the insulin signaling pathway". Eur. J. Biochem. (GERMANY) 234 (2): 656–60. DOI:10.1111/j.1432-1033.1995.656_b.x. ISSN 0014-2956. PMID 8536716. 
  32. ^ Yasukawa, H; Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle J N, Yoshimura A (March 1999). "The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop". EMBO J. (ENGLAND) 18 (5): 1309–20. DOI:10.1093/emboj/18.5.1309. ISSN 0261-4189. PMC 1171221. PMID 10064597. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1171221. 
  33. ^ Dif, F; Saunier E, Demeneix B, Kelly P A, Edery M (December 2001). "Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor". Endocrinology (United States) 142 (12): 5286–93. DOI:10.1210/en.142.12.5286. ISSN 0013-7227. PMID 11713228. 
  34. ^ Endo, T A; Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (June 1997). "A new protein containing an SH2 domain that inhibits JAK kinases". Nature (ENGLAND) 387 (6636): 921–4. DOI:10.1038/43213. ISSN 0028-0836. PMID 9202126. 
  35. ^ Pezet, A; Favre H, Kelly P A, Edery M (August 1999). "Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling". J. Biol. Chem. (UNITED STATES) 274 (35): 24497–502. DOI:10.1074/jbc.274.35.24497. ISSN 0021-9258. PMID 10455112. 
  36. ^ Ungureanu, Daniela; Saharinen Pipsa, Junttila Ilkka, Hilton Douglas J, Silvennoinen Olli (May. 2002). "Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1". Mol. Cell. Biol. (United States) 22 (10): 3316–26. DOI:10.1128/MCB.22.10.3316-3326.2002. ISSN 0270-7306. PMC 133778. PMID 11971965. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=133778. 
  37. ^ Shigematsu, H; Iwasaki H, Otsuka T, Ohno Y, Arima F, Niho Y (May. 1997). "Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity". J. Biol. Chem. (UNITED STATES) 272 (22): 14334–40. DOI:10.1074/jbc.272.22.14334. ISSN 0021-9258. PMID 9162069. 
  38. ^ Matsuguchi, T; Inhorn R C, Carlesso N, Xu G, Druker B, Griffin J D (January 1995). "Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL". EMBO J. (ENGLAND) 14 (2): 257–65. ISSN 0261-4189. PMC 398079. PMID 7530656. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=398079. 
  39. ^ Sayeski, P P; Ali M S, Safavi A, Lyles M, Kim S O, Frank S J, Bernstein K E (November 1999). "A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn". J. Biol. Chem. (UNITED STATES) 274 (46): 33131–42. DOI:10.1074/jbc.274.46.33131. ISSN 0021-9258. PMID 10551884. 
  40. ^ Olayioye, M A; Beuvink I, Horsch K, Daly J M, Hynes N E (June 1999). "ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases". J. Biol. Chem. (UNITED STATES) 274 (24): 17209–18. DOI:10.1074/jbc.274.24.17209. ISSN 0021-9258. PMID 10358079. 
  41. ^ Zhu, T; Goh E L, Lobie P E (April 1998). "Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. Fak is not required for stat-mediated transcription". J. Biol. Chem. (UNITED STATES) 273 (17): 10682–9. DOI:10.1074/jbc.273.17.10682. ISSN 0021-9258. PMID 9553131. 
  42. ^ Ryu, H; Lee J H, Kim K S, Jeong S M, Kim P H, Chung H T (August 2000). "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin". J. Immunol. (UNITED STATES) 165 (4): 2116–23. ISSN 0022-1767. PMID 10925297. 
  43. ^ Guo, D; Dunbar J D, Yang C H, Pfeffer L M, Donner D B (March 1998). "Induction of Jak/STAT signaling by activation of the type 1 TNF receptor". J. Immunol. (UNITED STATES) 160 (6): 2742–50. ISSN 0022-1767. PMID 9510175. 
  44. ^ Huang, L J; Constantinescu S N, Lodish H F (December 2001). "The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor". Mol. Cell (United States) 8 (6): 1327–38. DOI:10.1016/S1097-2765(01)00401-4. ISSN 1097-2765. PMID 11779507. 
  45. ^ Witthuhn, B A; Quelle F W, Silvennoinen O, Yi T, Tang B, Miura O, Ihle J N (July 1993). "JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin". Cell (UNITED STATES) 74 (2): 227–36. DOI:10.1016/0092-8674(93)90414-L. ISSN 0092-8674. PMID 8343951. 
  46. ^ Gual, P; Baron V, Lequoy V, Van Obberghen E (March 1998). "Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor". Endocrinology (UNITED STATES) 139 (3): 884–93. DOI:10.1210/en.139.3.884. ISSN 0013-7227. PMID 9492017. 
  47. ^ Kawazoe, Y; Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T (January 2001). "Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation". J. Exp. Med. (United States) 193 (2): 263–9. DOI:10.1084/jem.193.2.263. ISSN 0022-1007. PMC 2193341. PMID 11208867. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2193341. 
  48. ^ Sarkar, S; Pollack B P, Lin K T, Kotenko S V, Cook J R, Lewis A, Pestka S (December 2001). "hTid-1, a human DnaJ protein, modulates the interferon signaling pathway". J. Biol. Chem. (United States) 276 (52): 49034–42. DOI:10.1074/jbc.M103683200. ISSN 0021-9258. PMID 11679576. 
  49. ^ Takeshita, T; Arita T, Higuchi M, Asao H, Endo K, Kuroda H, Tanaka N, Murata K, Ishii N, Sugamura K (April 1997). "STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction". Immunity (UNITED STATES) 6 (4): 449–57. DOI:10.1016/S1074-7613(00)80288-5. ISSN 1074-7613. PMID 9133424. 
  50. ^ Prolactin-induced Jak2 phosphorylation of RUSH: a key element in Jak/RUSH signaling. Helmer RA, Panchoo M, Dertien JS, Bhakta SM, Hewetson A, Chilton BS. Mol Cell Endocrinol. 2010 August 30;325(1-2):143-9.

Further reading [link]

  • Berger R (2006). "[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders]". Pathol. Biol. 54 (4): 182–4. DOI:10.1016/j.patbio.2005.07.002. PMID 16084028. 
  • Pargade V, Darnige L, Gaussem P (2006). "[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera]". Ann. Biol. Clin. (Paris) 64 (1): 3–9. PMID 16420986. 
  • Staerk J, Kallin A, Royer Y et al. (2007). "JAK2, the JAK2 V617F mutant and cytokine receptors". Pathol. Biol. 55 (2): 88–91. DOI:10.1016/j.patbio.2006.06.003. PMID 16904848. 
  • Hsu HC (2007). "Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders". Journal of the Chinese Medical Association : JCMA 70 (3): 89–93. DOI:10.1016/S1726-4901(09)70337-5. PMID 17389152. 

External links [link]
Ligand
Cytokine receptor
Janus kinase
JAK1 · JAK2 · JAK3 · TYK2
Adaptor proteins
STAT1 · STAT2 · STAT3 · STAT4 · STAT5 · STAT6
PIAS1 · PIAS2 · PIAS3 · PIAS4
1, 2, 3, 4, 5, 6, 7
IRF1 · IRF2 · IRF3 · IRF4 · IRF5 · IRF6 · IRF7 · IRF8

https://wn.com/Janus_kinase_2

Podcasts:

Email this Page Play all in Full Screen Show More Related Videos
PLAYLIST TIME:
×
×
×
×